Sulfasalazine Resolves Joint Stiffness in a Rabbit Model of Arthrofibrosis

J Orthop Res. 2020 Mar;38(3):629-638. doi: 10.1002/jor.24499. Epub 2019 Nov 11.

Abstract

Joint stiffness due to fibrosis/capsule contracture is a seriously disabling complication of articular injury that surgical interventions often fail to completely resolve. Fibrosis/contracture is associated with the abnormal persistence of myofibroblasts, which over-produce and contract collagen matrices. We hypothesized that intra-articular therapy with drugs targeting myofibroblast survival (sulfasalazine), or collagen production (β-aminopropionitrile and cis-hydroxyproline), would reduce joint stiffness in a rabbit model of fibrosis/contracture. Drugs were encapsulated in poly[lactic-co-glycolic] acid pellets and implanted in joints after fibrosis/contracture induction. Capsule α-smooth muscle actin (α-SMA) expression and intimal thickness were evaluated by immunohistochemistry and histomorphometry, respectively. Joint stiffness was quantified by flexion-extension testing. Drawer tests were employed to determine if the drugs induced cruciate ligament laxity. Joint capsule fibroblasts were tested in vitro for contractile activity and α-SMA expression. Stiffness in immobilized joints treated with blank pellets (control) was significantly higher than in non-immobilized, untreated joints (normal) (p = 0.0008), and higher than in immobilized joints treated with sulfasalazine (p = 0.0065). None of the drugs caused significant cruciate ligament laxity. Intimal thickness was significantly lower than control in the normal and sulfasalazine-treated groups (p = 0.010 and 0.025, respectively). Contractile activity in the cells from controls was significantly increased versus normal (p = 0.001). Sulfasalazine and β-aminopropionitrile significantly inhibited this effect (p = 0.005 and 0.0006, respectively). α-SMA expression was significantly higher in control versus normal (p = 0.0021) and versus sulfasalazine (p = 0.0007). These findings support the conclusion that sulfasalazine reduced stiffness by clearing myofibroblasts from fibrotic joints. Statement of clinical significance: The results provide proof-of-concept that established joint stiffness can be resolved non-surgically. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:629-638, 2020.

Keywords: arthrofibrosis; intra-articular drug delivery; myofibroblast; sulfasalazine.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aminopropionitrile / chemistry
  • Animals
  • Collagen / chemistry
  • Contracture / pathology
  • Disease Models, Animal
  • Fibrosis
  • Hydroxyproline / chemistry
  • Joint Capsule / pathology
  • Joint Diseases / drug therapy*
  • Joint Diseases / pathology*
  • Male
  • Muscle Contraction
  • Myofibroblasts / physiology
  • Rabbits
  • Stress, Mechanical
  • Sulfasalazine / pharmacology*

Substances

  • Aminopropionitrile
  • Sulfasalazine
  • Collagen
  • Hydroxyproline